Cargando…
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
BACKGROUND: While clinical outcomes following immunotherapy have shown an association with tumor mutation load using whole exome sequencing (WES), its clinical applicability is currently limited by cost and bioinformatics requirements. METHODS: We developed a method to accurately derive the predicte...
Autores principales: | Roszik, Jason, Haydu, Lauren E., Hess, Kenneth R., Oba, Junna, Joon, Aron Y., Siroy, Alan E., Karpinets, Tatiana V., Stingo, Francesco C., Baladandayuthapani, Veera, Tetzlaff, Michael T., Wargo, Jennifer A., Chen, Ken, Forget, Marie-Andrée, Haymaker, Cara L., Chen, Jie Qing, Meric-Bernstam, Funda, Eterovic, Agda K., Shaw, Kenna R., Mills, Gordon B., Gershenwald, Jeffrey E., Radvanyi, Laszlo G., Hwu, Patrick, Futreal, P. Andrew, Gibbons, Don L., Lazar, Alexander J., Bernatchez, Chantale, Davies, Michael A., Woodman, Scott E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078889/ https://www.ncbi.nlm.nih.gov/pubmed/27776519 http://dx.doi.org/10.1186/s12916-016-0705-4 |
Ejemplares similares
-
Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013) -
You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015) -
PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “Exercising” an alternative viewpoint
por: Haymaker, Cara, et al.
Publicado: (2012) -
Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013) -
Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)